跳至主要内容
临床试验/NCT03497637
NCT03497637招募中不适用

Comparison of Non-Invasive Vessel Fractional Flow Reserve Calculated From Angiographic Images Versus Fractional Flow Reserve in Patients With Intermediate Coronary Artery Stenoses

Helios Health Institute GmbH9 个研究点 分布在 1 个国家目标入组 1,054 人开始时间: 2020年10月23日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
1,054
试验地点
9
主要终点
Major Adverse Cardiac Event (MACE) rate

研究概览

简要总结

This is a prospective, randomized, controlled, multicenter, open-label study designed to assess whether vFFR is non-inferior to FFR in assessment of intermediate coronary stenosis in terms of the occurrence of MACE during 12 months after randomization.

详细描述

Coronary angiography is insensitive to assess the physiologic significance of a coronary stenosis. Therefore, clinical guidelines support the use of pressure-derived fractional flow reserve (FFR) to assess the hemodynamic significance of coronary stenosis. Nevertheless, the penetration of FFR in clinical routine continues to be limited by its requirement for pharmacological vasodilation, prolonged procedure time and adverse systemic effects from adenosine.

Vessel-FFR (vFFR) is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on computation of two angiographic projections. The vFFR values at each point along the vessel are color-coded and superimposed on the 3D epicardial model and cut-off values of ≤0.80 identical to standard invasive FFR apply.

These developments may translate towards more physiology guided intervention bearing the potential to improve clinical outcomes in patients with stable CAD. The ability to derive FFR values from routinely performed coronary angiograms, without the practical drawbacks that limit invasive techniques, could have an important impact on daily clinical practice.

To date no randomized outcome-based clinical trial has compared an image-based FFR methodology with standard invasive FFR in terms of subsequent clinical outcomes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18 years
  • Willing to participate and able to understand, read and sign the informed consent document before the planned procedure
  • Eligible for coronary angiography and/or PCI
  • Coronary artery disease in one or more native major epicardial vessels or their branches by coronary angiogram with visually assessed de novo coronary stenosis in which the physiological severity of the lesion is in question (typically 40-80% diameter stenosis).
  • Stable angina or acute coronary syndrome (non-culprit vessels only and outside of primary intervention during acute STEMI or NSTE-ACS)
  • Participation in another interventional study

排除标准

  • Previous CABG with patent grafts to the interrogated vessel
  • Tandem stenoses separated by more than 10 mm that require separate pressure guide wire interrogation or PCI (not to be interrogated or treated as a single stenosis)
  • Total coronary occlusions
  • Hemodynamic instability (Killip class III-IV)
  • Heavily calcified or tortuous vessels
  • Terminal disease with life expectancy of less than 12 months
  • STEMI within 48 hours of procedure
  • Severe valvular heart disease
  • ACS patients with difficulty in assessing which the culprit lesion is
  • Significant contraindication to adenosine administration (e.g. Asthma bronchiale)
  • Pregnancy

结局指标

主要结局

Major Adverse Cardiac Event (MACE) rate

时间窗: 1 year

composite of cardiac death, non-fatal myocardial infarction or unplanned revascularization

次要结局

  • All-cause mortality(1, 2 and 5 years)
  • Repeat revascularization (PCI or CABG) assessed by structured telephone interview and verification by hospital reports in case of event(1, 2 and 5 years)
  • Each component of the primary endpoint assessed by structured telephone interview and verification by hospital reports(1, 2 and 5 years)
  • MACE during long-term follow-up(2 and 5 years)
  • Number of analyzable lesions in both treatment arms(at intervention)
  • Cross-over rate from the one strategy to the other(at intervention)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (9)

Loading locations...

相似试验